Company news

Recce Pharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Safety Committee Approves Expansion of Ph I/II DFI Trial

February 25, 2024

RCE Establishes Strategic Partnership in South-East Asia

February 5, 2024

Positive Ph I/II DFI Efficacy Data to Support Site Expansion

January 17, 2024

Murdoch Children's R327 Efficacy UTI in-vivo

December 27, 2023

RCE Awarded Further $11.17m Advanced Overseas Finding

December 15, 2023

RCE Awarded $43.7m AusIndustry Advanced Overseas Finding

December 14, 2023

Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo

December 13, 2023

Canadian Patent Granted for RECCE Anti-Infectives

November 22, 2023

Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial

November 6, 2023

Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis

October 23, 2023

Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial

September 22, 2023

Placement and Entitlement Offer

September 11, 2023

Opening R&D Address at World AMR Congress

September 7, 2023

RECCE Trademark Registered - Vietnam

September 6, 2023

Additional Positive Patient Cases - Special Access Scheme

August 31, 2023

Appendix 4E and Unaudited Preliminary Report

August 31, 2023

Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial

August 28, 2023

Patients Dosed in R327 Diabetic Foot Infection Trial

August 22, 2023

Phase I/II Burn Wound Infection Trial Stage 1 Complete

August 21, 2023

Positive Patients Update - Special Access Scheme

August 7, 2023

Australian Patent Granted for RECCE Anti-Infectives

August 3, 2023

Bonus Canadian R&D Rebate Received

July 28, 2023

Scientia Completes Cohort Dosing in Phase I/II UTI Trial

July 28, 2023

Scientia Doses Ahead of Schedule in Phase I/II UTI Trial

July 24, 2023

Clarification - 5x Higher Concentration in Urine & Plasma

July 20, 2023

Phase I Clinical Trial Data Review Complete

July 19, 2023

A$801,604 R&D Rebate Advance Received

July 12, 2023

First Cohort Dosed in Rapid Infusion Phase I/II UTI study

July 10, 2023

Ethics Approval for Phase I/II UTI Trial Expansion

June 29, 2023

Ethics Approval to Start Phase I/II (I.V.) Clinical Trial

April 17, 2023

New Family 4 Patent to be Granted for RECCE Anti-Infectives

April 10, 2023

Recce Receives Further A$973,144 R&D Advance

April 4, 2023

Corporate Presentation - WI Emergence 2023

March 22, 2023

Recce Selects CMAX for Phase I/II UTI Clinical Trial

February 19, 2023

A$6.21m Received from R&D Rebate Payments

January 24, 2023

JP Morgan Healthcare Conference

January 10, 2023

Australian Patent to be Granted for RECCE Anti-Infectives

January 9, 2023

Anti-Infective Research Unit est. at Murdoch Childrens

December 15, 2022

Approval to Start Phase I/II Diabetic Foot Ulcer Study

December 8, 2022

Anti-Infective Portfolio Update and Webinar details

October 18, 2022

Pause in trading

October 17, 2022

R327 COVID Study Update

October 17, 2022

Expansion and Acceleration of Clinical Programs

September 27, 2022

Appendix 4E

August 31, 2022

Phase I Clinical Trial of R327 I.V. - 6000mg Complete

August 21, 2022

Corporate Presentation - Aussie Equities Day 2022

July 28, 2022

Phase I Positive Safety Data - 4000mg Complete

June 21, 2022

Phase I Clinical Trial R327 Advances to 4000mg

May 20, 2022

Corporate Presentation - Biotech Investor Lunch

May 16, 2022

Phase I Clinical Trial R327 Advances to High Dose Cohort

April 12, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 45 decks. Every deck is listed under its year.